Ingrid Boere

Gemeente Rotterdam — Netherlands

Medicine · Health Sciences

29h-index6.0kcitations141works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(53), Endometrial and Cervical Cancer Treatments(49), Cancer Risks and Factors(22), Cancer Genomics and Diagnostics(16), PARP inhibition in cancer therapy(15)

Publications137 total

Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant
The Breast·2025Open Access
546 Sarilumab as a potential mitigator of ubamatamab (MUC16×CD3)-induced cytokine release syndrome (CRS) in patients with advanced ovarian cancer (OC) or endometrial cancer (EC)
Regular and Young Investigator Award Abstracts·2025Open Access
59 Bispecific antibody ubamatamab elicits patient-specific anti-tumor and immune responses in an ex vivo ovarian cancer platform
Regular and Young Investigator Award Abstracts·2025Open Access
TROFUSE-020/GOG-3101/ENGOT-CX20: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY COMPARING SACITUZUMAB TIRUMOTECAN MONOTHERAPY VS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR RECURRENT/METASTATIC CERVICAL CANCER
International Journal of Gynecological Cancer·2025
Abstract A129: Bispecific antibody Ubamatamab induces personalized anti-tumor immune responses in an ex vivo platform for ovarian cancer
Molecular Cancer Therapeutics·2025
Plaatsbepaling chemoradiatie in combinatie met immuuntherapie en rol van neoadjuvante chemotherapie bij lokaal gevorderd cervixcarcinoom
Medische oncologie·2025
TroFuse-020/GOG-3101/ENGOT-cx20: A phase III, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-line treatment for recurrent or metastatic cervical cancer
Gynecologic Oncology·2025
1068P Second progression-free survival (PFS2) and subsequent treatment in patients (pts) with folate receptor alpha (FR⍺)-positive platinum-resistant ovarian cancer (PROC) treated with mirvetuximab soravtansine (MIRV) vs investigator’s choice chemotherapy (ICC): Phase III MIRASOL trial
Annals of Oncology·2025Open Access
1118P Time to quality of life (QoL) deterioration in patients (pts) with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/rEC) and by population subgroups in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Annals of Oncology·2025
Updated duration of response for patients receiving dostarlimab plus carboplatin-paclitaxel treatment compared with patients receiving placebo plus carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Gynecologic Oncology·2025
Emerging Radiopharmaceuticals Beyond <scp>FDG</scp> for Ovarian Cancer: A Review of Advances in Nuclear Medicine
Cancer Medicine·2025Open Access
A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel
Therapeutic Advances in Medical Oncology·2025Open Access
Final overall survival analysis among patients with folate receptor alpha-positive, platinum-resistant ovarian cancer treated with mirvetuximab soravtansine versus investigator's choice chemotherapy in phase II MIRASOL (GOG-3045/ENGOT-ov55) study
Gynecologic Oncology·2025· 1 cited
Molecular diversity in uterine carcinosarcoma: Beyond TP53
Gynecologic Oncology·2025
Time to subsequent therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) receiving dostarlimab plus carboplatin-paclitaxel (DOST+CP) compared with pts receiving placebo plus CP (PBO+CP) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
Journal of Clinical Oncology·2025
TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer.
Journal of Clinical Oncology·2025
655 Immune cell function during and after bone marrow sparing versus non-bone marrow sparing EBRT in cervical cancer
Radiotherapy and Oncology·2025
1236 13 years’ experience of the Dutch Advisory Board “Cancer during pregnancy” (ABCIP-NLs), with a focus on radiation therapy
Radiotherapy and Oncology·2025
Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B)
Contemporary Clinical Trials Communications·2025· 2 citedOpen Access
Consensus on Treatment for Inoperable and Peroperatively Unresectable Ovarian Cancer: A Modified Delphi Study
2025Open Access
page 1 of 7Next →

Frequent Co-authors

Frédéric Amant(13), Kristel Van Calsteren(12), Petronella B. Ottevanger(11), M Halaška(10), Christianne Lok(10), Mina Mhallem Gzirí(9), Robert Fruscio(8), Sandro Pignata(7), Susana Banerjee(7), David Cibula(7), Ignace Vergote(7), Charlotte Maggen(7), Richard T. Penson(6), Magali Verheecke(6), Fedro A. Peccatori(6), Elyce Cardonick(6), Petronella O. Witteveen(6), Jonathan A. Ledermann(5), Amit M. Oza(5), Nicoletta Colombo(5)